Senologie - Zeitschrift für Mammadiagnostik und -therapie, Inhaltsverzeichnis Senologie - Zeitschrift für Mammadiagnostik und -therapie 2019; 16(02): 100-102DOI: 10.1055/a-0901-3729 Aktuell diskutiert © Georg Thieme Verlag KG Stuttgart · New York Stellungnahme der DGS zu Palbociclib (Ibrance®) Artikel empfehlen Abstract Artikel einzeln kaufen Volltext Referenzen Literatur 1 Weide R, Feiten S, Friesenhahn V. et al. Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors. Springerplus 2014; 3: 535 2 Gennari A, Conte P, Rosso R. et al. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005; 104: 1742-1750 3 Joy AA, Ghosh M, Fernandes R. et al. Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines. Curr Oncol 2015; 22 (Suppl. 01) S29-S42 4 Partridge AH, Rumble RB, Carey LA. et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2014; 32: 3307-3329 5 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.0, 2017 AWMF Registernummer: 032-045OL. Im Internet: http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/ . Stand 29.4.2019 6 Cardoso F, Costa A, Senkus E. et al. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol 2017; 28: 3111 7 Rugo HS, Rumble RB, Macrae E. et al. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Clin Oncol 2016; 34: 3069-3103 8 Cardoso F, Bischoff J, Brain E. et al. A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women. Cancer Treat Rev 2013; 39: 457-465 9 Hamilton E, Infante JR. Targeting CDK4/6 in patients with cancer. Cancer Treat Rev 2016; 45: 129-138 10 Finn RS, Martin M, Rugo HS. et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 2016; 375: 1925-1936 11 Turner NC, Ro J, Andre F. et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med 2015; 373: 209-219 12 Hortobagyi GN, Stemmer SM, Burris HA. et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med 2016; 375: 1738-1748 13 Goetz MP, Toi M, Campone M. et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 2017; 35: 3638-3646 14 Mauri D, Pavlidis N, Polyzos NP. et al. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 2006; 98: 1285-1291 15 Hartkopf AD, Huober J, Volz B. et al. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors – Data from the German PRAEGNANT breast cancer registry. Breast 2018; 37: 42-51 16 Jeselsohn R, Buchwalter G, De Angelis C. et al. ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol 2015; 12: 573-583 17 Fribbens C, O'Leary B, Kilburn L. et al. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. J Clin Oncol 2016; 34: 2961-2968 18 Taylor CW, Green S, Dalton WS. et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol 1998; 16: 994-999 19 AstraZeneca, Fachinformation Zoladex® (Goserelin) 3,6 mg Implantat. Stand April 2015 20 Arbeitsgemeinschaft Gynäkologische Onkologie e.V. Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer – Version 1. 2018 Im Internet: https://www.ago-online.de/fileadmin/downloads/leitlinien/mamma/2018-03/EN/Gesamt_PDF_Englisch/Updated_Guidelines_2018.pdf . Stand: 29.4.2019 21 Muller V, Nabieva N, Haberle L. et al. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. Breast 2018; 37: 154-160 22 Fasching PA, Esteva FJ, Pivot X. et al. Patient-reported outcomes in advanced breast cancer treated with ribociclib + fulvestrant: results from MONALEESA-3. Ann Oncol 2018; 23 Schnipper LE, Davidson NE, Wollins DS. et al. Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. J Clin Oncol 2016; 34: 2925-2934 24 Cherny NI, Sullivan R, Dafni U. et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015; 26: 1547-1573 25 Turner NC, Slamon DJ, Ro J. et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med 2018; 379: 1926-1936 26 Gemeinsamer Bundesausschuss, Tragende Gründe zum Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL). Anlage XII: Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V; Palbociclib [online] (2017). Im Internet: https://www.g-ba.de/downloads/40-268-4388/2017-05-18_AM-RL-XII_Palbociclib_D-264_TrG.pdf ; Zugriff: 15.01.2019 27 Cioroiu C, Weimer LH. Update on Chemotherapy-Induced Peripheral Neuropathy. Curr Neurol Neurosci Rep 2017; 17: 47 28 Payne DL, Nohria A. Prevention of Chemotherapy Induced Cardiomyopathy. Curr Heart Fail Rep 2017; 14: 398-403 29 Pfizer, Dossier zur Nutzenbewertung gemäß § 35a SGB V – Palbociclib (IBRANCE®) – Modul 1 – Stand: 28.09.2018.
